Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2025 Financial Results Third Quarter 2025 and Recent Highlights NEWTOWN SQUARE, PA, November 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent Company progress. "Our late-stage firmonertinib p ...